Holen Sie sich die Stockscreener-App
9.22
3.20%
0.29
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$8.93
Offen:
$8.975
24-Stunden-Volumen:
4.21M
Relative Volume:
0.28
Marktkapitalisierung:
$10.61B
Einnahmen:
$14.33B
Nettoeinkommen (Verlust:
$-3.79B
KGV:
-2.9085
EPS:
-3.17
Netto-Cashflow:
$1.84B
1W Leistung:
+2.97%
1M Leistung:
+4.84%
6M Leistung:
-25.98%
1J Leistung:
-12.98%
1-Tages-Spanne:
$8.88
$9.22
1-Wochen-Bereich:
$8.84
$9.22
52-Wochen-Spanne:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.215 | 10.61B | 14.33B | -3.79B | 1.84B | -3.17 |
|
RGC
Regencell Bioscience Holdings Ltd
|
16.11 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.89 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.41 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.45 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Andrew Smith Reports 2.90% Stake In Smarter Web Company As At June 13 Vs Prior Stake Of 10.39% - MarketScreener
Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, - openPR.com
Viatris Inc’s Mixed Bag: Down -29.49% in 6 Months, Down 2.28% in 30 Days - investchronicle.com
3 Reasons to Avoid VTRS and 1 Stock to Buy Instead - Yahoo Finance
Viagra ‘Make Love Last’ wins Pharma Grand Prix after artfully working around Chinese ad regulations - Ad Age
ViatrisMAKE LOVE LAST59s - Ad Age
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Viatris Announces Q2 2025 Earnings Call: Key Details for Investors Released - Stock Titan
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris - sharewise
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Transcript : Viatris Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - marketscreener.com
Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of Viatris (VTRS) with Neutral Recommendation - Nasdaq
Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout - Insider Monkey
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga
Goldman Sachs Initiates Coverage on Viatris (VTRS) with Neutral Rating | VTRS Stock News - GuruFocus
Goldman Sachs starts Viatris stock coverage with neutral rating - Investing.com
Transcript : Viatris Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - marketscreener.com
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals And Viatris - Barchart.com
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VTRS - TradingView
Class Action Lawsuit Filed: Viatris Inc. (VTRS)Join by June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
June 3, 2025 Deadline Approaching: Join Class Action Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris (VTRS) Reports Positive Phase 3 Trial Results for Night Driving Treatment - GuruFocus
Viatris sees positive top-line phase 3 results for night driving impairment asset - Seeking Alpha
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewswire
June 3, 2025 Deadline: Join Class Action Lawsuit Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming DeadlinesVTRS - FinancialContent
Viatris reports success in phase 3 trial of night vision treatment MR-142 - Investing.com India
Viatris (VTRS) Reports Positive Results from LYNX-2 Trial for Eye Treatment | VTRS Stock News - GuruFocus
VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris - GlobeNewswire
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - PR Newswire
Shareholders of Viatris Inc. (VTRS): Protect Your Rights Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Viatris Inc. (VTRS)June 3, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with ... - Bluefield Daily Telegraph
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action – VTRS - TradingView
Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Lost Money on Viatris Inc. (VTRS)? Urged to Join Class Action Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - StreetInsider
Did You Lose Money on Viatris Inc. (VTRS)? Levi & Korsinsky Urges Investors to Act Before June 3, 2025 - Stockhouse
VTRS CLASS NOTICE: Viatris Inc. Investors may have been - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - marketscreener.com
VIATRIS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc.VTRS - Business Wire
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viatris Inc-Aktie (VTRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Le Goff Corinne | Chief Commercial Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
41,112 |
0 |
60,441 |
| FINNEY ELISHA W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
37,832 |
| Le Goff Corinne | Chief Commercial Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
37,894 |
0 |
36,721 |
| Campbell Paul | See Remarks |
Mar 04 '25 |
Option Exercise |
0.00 |
207,325 |
0 |
328,250 |
| Campbell Paul | See Remarks |
Mar 03 '25 |
Option Exercise |
0.00 |
19,348 |
0 |
144,590 |
| Vivaldi Coelho Rogerio | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
21,691 |
0 |
21,691 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
96,431 |
0 |
266,825 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
146,700 |
0 |
221,178 |
| PARRISH MARK W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
140,395 |
| Lyons Dillon JoEllen | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
77,691 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):